OSL GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.26 HKD | +1.15% |
|
-2.05% | -56.74% |
| Jun. 17 | Osl Group Limited Announces Appointment of Yang Huan Independent Non-Executive Directors | CI |
| Jun. 03 | Oncosil Medical Treats 200th Pancreatic Cancer Patient with Proprietary Device | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Blockchain & Cryptocurrency
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -56.74% | 422M | - | ||
| +25.36% | 53.54B | - | ||
| +50.31% | 9.06B | - | - | |
| +72.10% | 2.3B | - | ||
| +146.20% | 419M | - | - | |
| +24.13% | 411M | - | - | |
| -55.94% | 307M | - | - | |
| -.--% | 121M | - | - | |
| -66.06% | 118M | - | - | |
| -37.29% | 87.95M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 863 Stock
- Ratings OSL Group Limited
